Prevalence of muscle weakness in IBD and effect of treatment on muscle weakness

Prevalence and impact of sarcopenia and frailty in inflammatory bowel disease, and the effect of multi-modal interventions on sarcopenia and clinical outcomes in patients with inflammatory bowel disease - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/01/061649

Enrollment

300

Registered

2024-01-19

Start date

Unknown

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K509- Crohns disease, unspecified Health Condition 2: K519- Ulcerative colitis, unspecified

Interventions

Intervention1: High protein anti-inflammatory diet (HP AID) along with resistance plus endurance exercises: High protein diet providing 1.2 gm/kg of protein along with anti inflammatory diet in which

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion Criteria (First phase) 1) Age between 18 years to 65 years 2) Patients with aggressive IBD as defined above 3) Provide informed consent Inclusion Criteria (Second phase) 1) Patients found to be having sarcopenia during first phase of the study randomized into intervention arm and standard treatment arm 2) Provide informed consent

Exclusion criteria

Exclusion criteria: Exclusion Criteria (First phase) 1) Patients with other comorbid illnesses (end stage liver, kidney, cardiac illnesses, neuromuscular illnesses and terminal cancer patients) 2) Pregnancy and Lactation Exclusion Criteria (Second phase) 1) Patients with other comorbid illnesses (end stage liver, kidney, cardiac illnesses, neuromuscular illnesses and terminal cancer patients) 2) Pregnancy and lactation 3) Inability to perform exercise 4) Inability to adhere to prescribed diet / nutritional supplements 5) Patients requiring surgery 6) Patients enrolled in other trials

Design outcomes

Primary

Measure	Time frame
1.Prevalence of sarcopenia in IBD / CD / UC patients 2.Improvement in HGS after 24 weeks of intervention (HP AID & resistance plus endurance exercises) Timepoint: 0 and 24 weeks	—

Secondary

Measure	Time frame
1. Impact of HP AID and resistance + endurance exercises on sarcopenia as well as on clinical outcomes 2. Prevalence of frailty in IBD patients 3. Predictors of sarcopenia and frailty 4. Impact of sarcopenia and frailty on various clinical outcomes 5. Sn, Sp, PPV, NPV and accuracy of various measures of sarcopenia Timepoint: 0 and 24 weeks	—

Countries

India

Contacts

Public ContactVishal Singh Chauhan

AIIMS, New Delhi

dr.saurabhkedia@yahoo.com9868428535

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026